CDT Notes Sarborg Publication of PRISM Framework Expanding AI
CDT Equity Inc., a Nasdaq-listed biopharmaceutical development company, acknowledges Sarborg Limited's publication of the PRISM framework research paper. Holding a 20% stake, CDT views this advancement as a significant expansion of Sarborg’s proprietary Signature Intelligence platform from pharmaceuticals into agrichemical and broader industrial bi…